drugset / Trial / NCT01242748

A Degarelix Trial in Patients With Prostate Cancer

NCT01242748

Phase 3 Terminated 288 enrolled Ferring Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.

Timeline

Start
2010-10
Primary completion
2011-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 480 mg Subcutaneous
Comparator Goserelin Other / unclassified 10.8 mg Subcutaneous

Indications